Tema Neuroscience and Mental Health ETF (NASDAQ: MNTL)

Latest news for Tema Neuroscience and Mental Health ETF (NASDAQ:MNTL)

Healthcare

Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies

Vertex Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc.

Eli Lilly & Co.

Alnylam Pharmaceuticals Inc.

Argenx Se Spon Adr Each Rep 1 Ord Shs

Neurocrine Biosciences Inc

Denali Therapeutics Inc

Biogen Inc.

Teva Pharmaceutical Industries Ltd Sponsored Adr

Crinetics Pharmaceuticals Inc Com

Tema Neuroscience and Mental Health ETF

BENZINGA VIRTUAL HEALTHCARE SUMMIT 2024

Health Care

Events

CSE:BHSC

ELTX

MNTL

ZVSA

The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don&#39;t miss out on this must-attend event!

Benzinga&#39;s 2024 Virtual Healthcare Summit: What&#39;s Next In Health?

Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is looking for Q1 Adj EPS of $1.65-1.71 vs $1.57 analyst estimate. sees sales of $1.265 billion-1.285 billion vs $1.26 billion estimate.

News

Guidance

KEYS

Keysight Techs Sees Q1 Adj EPS $1.65-1.71 vs $1.57 Est; Sees Sales $1.265B-1.285B vs $1.26B Est

Concentra Group To Replace Myers Industries In S&P SmallCap 600 Effective Prior To Opening Of Trading On November 27

AZTA

Azenta To Replace Envestnet In S&P SmallCap 600 Effective Prior To The Opening Of Trading On November 25

FLEX

Flex To Replace Azenta In S&P MidCap 400

Donald Trump has announced several picks for potential nominees for his White House administration since winning the <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">2024 presidential election.</a>
While the picks still have to be nominated and approved in many cases, voters were recently asked to share whether they approve of or disapprove of his current selections.
What Happened: Trump's announced picks have generated plenty of discussion on social media and across the political spectrum with the announced picks of Matt Gaetz <a href="https://www.benzinga.com/news/legal/24/11/41956594/matt-gaetz-is-trumps-attorney-general-pick-would-be-top-cop-is-under-house-ethics-investigation">as attorney general</a> and Robert F. Kennedy Jr. leading the Health and Human Services generating the most buzz.
A new Morning Consult <a href="https://pro.morningconsult.com/analysis/trump-transition-nominees-approval">poll </a>asked voters how they think Trump is doing with his transition.
The poll found that 54% of voters approve of Trump's handling of his transition since winning the 2024 election, with 38% disapproving and 8% saying they don't know or had no opinion.
Split by political party, Republicans showed a higher approval rating (93%) of Trump's handling of the transition compared to Democrats (20%). Independent voters were more split with 46% approving, 40% disapproving and 14% having no opinion or saying they don't know.
Trump's 54% approval rating is only six points below the 60% approval rating President Joe Biden had four years ago from a Morning Consult poll.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Personnel Pick Ratings: Here are the approval and disapproval ratings of recent personnel picks by Trump for his next White House term.
<ul>
<li>Mike Huckabee, U.S. Ambassador to Israel: 44% approval, 31% disapproval, 25% no opinion</li>
<li>Marco Rubio, Secretary of State: 45% approval, 34% disapproval, 21% no opinion</li>
<li>Elise Stefanik, U.S. Ambassador to the United Nations: 38% approval, 29% disapproval, 33% no opinion</li>
<li>Stephen Miller, Deputy White House Chief of Staff: 36% approval, 30% disapproval, 34% no opinion</li>
<li>Tulsi Gabbard, Director of National Intelligence: 39% approval, 33% disapproval, 29% no opinion</li>
<li>Robert F. Kennedy Jr., Health and Human Services Secretary: 44% approval, 39% disapproval, 16% no opinion</li>
<li>Elon Musk, co-leader of the Department of Government Efficiency: 45% approval, 40% disapproval, 15% no opinion</li>
<li>Vivek Ramaswamy, co-leader of the Department of Government Efficiency: 39% approval, 34% disapproval, 27% no opinion</li>
<li>Lee Zeldin, Environmental Protection Agency Administration: 34% approval, 29% disapproval, 37% no opinion</li>
<li>Pete Hegseth, Secretary of Defense: 37% approval, 32% disapproval, 31% no opinion</li>
<li>Kristi Noem, Secretary of Homeland Security: 37% approval, 33% disapproval, 30% no opinion</li>
<li>Matt Gaetz, Attorney General: 34% approval, 41% disapproval, 25% no opinion</li>
</ul>
Why It's Important: The selection of Gaetz could face the most scrutiny by members of Congress if he is formally nominated. The Republican resigned from Congress the same day Trump announced the attorney general role for him.
Gaetz was investigated by the Department of Justice for sex trafficking before it declined to charge the congressman.
The former Congressman was under investigation by the House Ethics Committee for sexual misconduct. Allegations against the Trump ally include sexual misconduct, illicit drug use, accepting improper gifts and more. Gaetz has denied the allegations.
Gaetz is the only person in the poll to receive a higher percentage of disapproval than approval.
When it comes to disapproval, Gaetz ranks first at 41% followed by Tesla CEO Elon Musk at 40%.
Musk, who has been named by Trump to lead the Department of Government Efficiency and cut government spending, also has the <a href="https://www.benzinga.com/politics/24/11/41993300/elon-musks-favorability-with-gop-voters-nearly-as-high-as-j-d-vance-how-views-of-billionaire-changed-among-political-parties">highest approval rating</a> at 45%, tied with Marco Rubio.
Musk has the lowest percent of voters saying no opinion, showing how opinionated voters are of his potential selection. Musk maintains a positive net approval rating of 45% to a disapproval rating of 40%.
Kennedy Jr. ranks among the highest for approval at 44% and for disapproval at 39%. Like Musk, Kennedy also has a low amount of voters saying they have no opinion at 16%.
Huckabee has the highest net approval rating in the poll at 13 points.
This poll was taken before Trump announced Dr. Mehmet Oz as his choice as <a href="https://www.benzinga.com/general/health-care/24/11/42077057/trump-picks-dr-oz-as-centers-for-medicare-and-medicaid-services-administrator">Centers For Medicare and Medicaid Services administrator</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/42036132/trump-wants-matt-gaetz-confirmed-100-so-does-the-cannabis-industry">Trump Wants Matt Gaetz Confirmed &#8216;100%,&#8217; So Does The Cannabis Industry</a></li>
</ul>
Photo: Musk, White House, public domain; Trump and Getz, Shutterstock

Politics

Donald Trump's Personnel Picks: New Poll Finds Elon Musk With Highest Approval By Voters, Matt Gaetz With Highest Disapproval

Telsey Advisory Group analyst Joseph Feldman maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and raises the price target from $92 to $100.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on Walmart, Raises Price Target to $100

ZTO Cuts 2024 Outlook For Parcel Volume From 34.73B - 35.64B To 33.7B - 33.9B Based On Current Market And Operating Conditions

KITT

Nauticus Robotics Enters Strategic Collaboration With SeaTrepid To Integrate And Test Its ToolKITT Software On Remotely Operated Vehicles

Canaccord Genuity analyst Caitlin Cronin maintains Vericel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCEL#NASDAQ">VCEL</a>) with a Buy and maintains $60 price target.

VCEL

Canaccord Genuity Maintains Buy on Vericel, Maintains $60 Price Target

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $80 price target.

RYTM

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Maintains $80 Price Target

Earnings

LDWY

Lendway Q3 EPS From Continuing Operations $(0.67) Up From $(0.85) YoY, Sales $6.6M

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and maintains $39 price target.

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Maintains $39 Price Target

The Company intends to use the net proceeds from this offering, together with proceeds from the expected issuance of up to $650 million aggregate principal amount of new senior secured notes, borrowings under our revolving credit facility and cash on hand, to fund the consideration payable by us in the previously-announced, pending acquisition of all of the equity interests in Guardian Pipeline, L.L.C., Midwestern Gas Transmission Company and Viking Gas Transmission Company from ONEOK Partners Intermediate Limited Partnership and Border Midwestern Company.

Offerings

ZTO DT Midstream Commences Public Offering Of $300M Of Shares Of Common Stock

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $90 price target.

NTLA

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $90 Price Target

President-elect Donald Trump on Tuesday said he will nominate celebrity physician Dr. Mehmet Oz to lead the Centers for <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Medicare and Medicaid Services (CMS). </a>
The Details: Trump announced Dr. Oz as his pick for CMS administrator in a statement Tuesday afternoon.&nbsp;
"Our broken Healthcare System harms everyday Americans, and crushes our country's budget," Trump said.&nbsp;
"Dr. Oz will be a leader in incentivizing disease prevention, so we get the best results in the world for every dollar we spend on health care in our Great Country," Trump said. "He will also cut waste and fraud within our country's most expensive government agency, which is a third of our nation's health care spend, and a quarter of our entire national budget."
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
Dr. Oz has a history of offering unproven medical advice and has said his goal was to "empower" Americans to take control of their health, according to the New York Times. He <a href="https://www.nytimes.com/2021/12/26/us/politics/dr-oz-medical-advice.html">promoted the use</a> of hydroxychloroquine as an effective treatment against COVID-19 in the early days of the pandemic, before reversing course and advising patients to wait for evidence from randomized trials.&nbsp;
CMS, an agency within the Health and Human Services Department (HHS), oversees several major health care programs including Medicare, Medicaid, the Children's Health Insurance Program and the Healthcare.gov insurance marketplace exchange. Federal spending on the four programs is $1.6 trillion, or nearly 25% of the entire federal budget.
Last week, Trump announced his intention to nominate another <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">controversial figure,</a> Robert Kennedy Jr., to head the HHS.&nbsp; Other unconventional selections include Trump's choices of former Rep. Matt Gaetz for U.S. attorney general and Fox News host Pete Hegseth for defense secretary.
Chiquita Brooks-LaSure is the current CMS administrator under the Biden administration.&nbsp;
Following Trump&#8217;s announcement, investors may want to monitor shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer nationwide, and shares of Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid insurers.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: G. Holland via Shutterstock

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Trump Picks Dr. Oz As Centers For Medicare And Medicaid Services Administrator

Canaccord Genuity analyst Austin Moeller maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Hold and maintains $76 price target.

ENPH

Canaccord Genuity Maintains Hold on Enphase Energy, Maintains $76 Price Target

The offering consists of $500 million aggregate principal amount of senior secured notes due 2026&nbsp;at a price to the public of 99.948% of their face value and $750&nbsp;million aggregate principal amount of senior secured notes due 2034 at a price to the public of 99.903% of their face value.

Vistra Reveals Pricing Of Private Offering Of $1.25B Of Senior Secured Notes

Canaccord Genuity analyst Sumant Kulkarni maintains Cybin (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#AMEX">CYBN</a>) with a Buy and maintains $86 price target.

CYBN

Canaccord Genuity Maintains Buy on Cybin, Maintains $86 Price Target

Advanced Environmental Recycling Technologies

AERT

Aeries Technology Q2 EPS $(0.05), Sales $16.9M Down From $17.6M YoY

Canaccord Genuity analyst Brian McNamara maintains Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) with a Buy and maintains $3 price target.

Canaccord Genuity Maintains Buy on Solo Brands, Maintains $3 Price Target

Circle March 20 on your calendars! Starting at 10:25 a.m. EST Wednesday, the Benzinga Virtual Healthcare Summit 2024 is the place to be. Imagine a digital room buzzing with the likes of Beachbody&#8217;s Mark Goldston, Autonomix Medical&#8217;s Lori Bisson, and IGC Pharma&#8217;s Ram Mukunda (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>). It&#8217;s not just another webinar; it&#8217;s where the future of healthcare <a href="https://www.benzinga.com/general/health-care">starts to take shape.</a>



<h3 class="wp-block-heading">Who&#8217;s Who And What You Need To Know</h3>



The speaker lineup reads like a who&#8217;s who of healthcare. Elicio Therapeutics&#8217; Robert Connelly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NYSE">ELTX</a>) and Sparrow Pharmaceuticals&#8217; Robert Jacks share the digital stage. Don Duffy from ICR throws down some complex numbers, reminding us that with $4.5 trillion spent on U.S. healthcare, &#8220;Healthcare will continue to drive the economy as [healthcare] continues to soar.&#8221;



Wedbush&#8217;s Laura Chico, Ph., cuts through the market noise with a clear message: Despite a tough market, biotech&#8217;s foundation is strong. Over at Tema ETFs, which includes the Tema Neuroscience and Mental Health ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTL#NASDAQ">MNTL</a>), David Song is betting on big product launches in 2024, especially in the obesity and neurological fields.



<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/19145607/2231044_CCCFloridaGIF_V2_031124-20.gif" alt="" class="wp-image-257936" style="width:522px;height:auto"/></a></figure>



<h3 class="wp-block-heading">Forward-Thinking Fun</h3>



But wait, there&#8217;s more! Ilan Sobel of BioHarvest Sciences (CSE:<a class="ticker" href="https://www.benzinga.com/stock/BHSC#CSE">BHSC</a>) teases his conversation, anticipating a future where AI and personalized medicine are the norms, not the exceptions. &#8220;In 2024, we will see more integration of AI into healthcare systems,&#8221; he predicts, pointing to a future where health tech is as common as smartphones.



Robert Connelly believes 2024 will be a big year for cancer immunotherapy. Meanwhile, Steve Glover from ZyVersa Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NYSE">ZVSA</a>) is all about the power of partnerships, asserting that biotechs are now leading the charge in patient-focused healthcare innovations.



<h3 class="wp-block-heading">Why You Can&#8217;t-Miss It</h3>



This isn&#8217;t just another online meet-up. The Benzinga Virtual Healthcare Summit 2024 is where the heartbeat of healthcare tomorrow can be heard loud and clear. From eye-opening presentations to fireside chats that feel like sitting by a cozy hearth, this event is where the healthcare community comes to dream big. Don&#8217;t miss out on this day-long journey into what&#8217;s next for health—your future self will thank you.



Also Read: <a href="https://www.benzinga.com/markets/cannabis/24/03/37830087/goodbye-to-weed-posts-in-colorado-lawmakers-target-social-media-promotion-of-cannabis-and-psyche">Goodbye To Weed Posts In Colorado? Lawmakers Target Social Media Promotion Of Cannabis And Psychedelics</a>



The&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>&nbsp;is returning to Florida in a new venue in Hollywood on April 16 and 17, 2024. The two-day event at&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">The Diplomat Beach Resort</a>&nbsp;will be a chance for entrepreneurs, both large and small, to network, learn, and grow.&nbsp;Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars — this conference is the go-to event of the year for the cannabis world.&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Get your tickets now on&nbsp;</a><a href="http://bzcannabis.com/" target="_blank" rel="noreferrer noopener">bzcannabis.com</a><a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">&nbsp;– Prices will increase very soon!</a>



Join the <a href="https://www.benzinga.com/events/virtual-healthcare-summit-2024/">Benzinga Virtual Healthcare Summit 2024</a> below.



<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Benzinga Virtual HealthCare Summit 2024" width="500" height="281" src="https://www.youtube.com/embed/KViZoUFoTOk?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen></iframe>
</div></figure>



This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.



Image: Benzinga

Comments

Tema Neuroscience and Mental Health ETF

News

Latest news for Tema Neuroscience and Mental Health ETF (NASDAQ:MNTL)

Tuesday, March 19, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga